Concord Biotech Statistics

Total Valuation

Concord Biotech has a market cap or net worth of INR 225.03 billion. The enterprise value is 222.23 billion.

Market Cap	225.03B
Enterprise Value	222.23B

Important Dates

The next estimated earnings date is Monday, February 10, 2025.

Earnings Date	Feb 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Concord Biotech has 104.62 million shares outstanding. The number of shares has decreased by -0.05% in one year.

Current Share Class	n/a
Shares Outstanding	104.62M
Shares Change (YoY)	-0.05%
Shares Change (QoQ)	+0.08%
Owned by Insiders (%)	46.47%
Owned by Institutions (%)	14.89%
Float	24.88M

Valuation Ratios

The trailing PE ratio is 68.61 and the forward PE ratio is 52.10. Concord Biotech's PEG ratio is 1.85.

PE Ratio	68.61
Forward PE	52.10
PS Ratio	20.72
PB Ratio	14.15
P/TBV Ratio	14.16
P/FCF Ratio	116.07
P/OCF Ratio	n/a
PEG Ratio	1.85

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 47.67, with an EV/FCF ratio of 114.62.

EV / Earnings	67.77
EV / Sales	20.47
EV / EBITDA	47.67
EV / EBIT	53.88
EV / FCF	114.62

Financial Position

The company has a current ratio of 6.60, with a Debt / Equity ratio of 0.00.

Current Ratio	6.60
Quick Ratio	4.43
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.02
Interest Coverage	319.22

Financial Efficiency

Return on equity (ROE) is 22.27% and return on invested capital (ROIC) is 17.39%.

Return on Equity (ROE)	22.27%
Return on Assets (ROA)	15.58%
Return on Capital (ROIC)	17.39%
Revenue Per Employee	7.88M
Profits Per Employee	2.38M
Employee Count	1,377
Asset Turnover	0.65
Inventory Turnover	1.17

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +42.96% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+42.96%
50-Day Moving Average	1,991.63
200-Day Moving Average	1,728.81
Relative Strength Index (RSI)	56.95
Average Volume (20 Days)	77,446

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Biotech had revenue of INR 10.86 billion and earned 3.28 billion in profits. Earnings per share was 31.35.

Revenue	10.86B
Gross Profit	8.10B
Operating Income	4.13B
Pretax Income	4.42B
Net Income	3.28B
EBITDA	4.65B
EBIT	4.13B
Earnings Per Share (EPS)	31.35

Full Income Statement

Balance Sheet

The company has 2.84 billion in cash and 34.24 million in debt, giving a net cash position of 2.80 billion or 26.79 per share.

Cash & Cash Equivalents	2.84B
Total Debt	34.24M
Net Cash	2.80B
Net Cash Per Share	26.79
Equity (Book Value)	15.90B
Book Value Per Share	151.99
Working Capital	7.93B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.99 billion and capital expenditures -1.06 billion, giving a free cash flow of 1.94 billion.

Operating Cash Flow	2.99B
Capital Expenditures	-1.06B
Free Cash Flow	1.94B
FCF Per Share	18.53

Full Cash Flow Statement

Margins

Gross margin is 74.57%, with operating and profit margins of 38.06% and 30.20%.

Gross Margin	74.57%
Operating Margin	38.06%
Pretax Margin	40.68%
Profit Margin	30.20%
EBITDA Margin	42.85%
EBIT Margin	38.06%
FCF Margin	17.86%

Dividends & Yields

This stock pays an annual dividend of 8.75, which amounts to a dividend yield of 0.41%.

Dividend Per Share	8.75
Dividend Yield	0.41%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	27.91%
Buyback Yield	0.05%
Shareholder Yield	0.45%
Earnings Yield	1.46%
FCF Yield	0.86%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a